

RESEARCH ARTICLE

# Development and Evaluation of a Novel Mucoadhesive Film Containing *Acmella oleracea* Extract for Oral Mucosa Topical Anesthesia

Verônica Santana de Freitas-Blanco<sup>1,2</sup>, Michelle Franz-Montan<sup>1</sup>, Francisco Carlos Groppo<sup>1</sup>, João Ernesto de Carvalho<sup>1,2,3</sup>, Glyn Mara Figueira<sup>2</sup>, Luciano Serpe<sup>1</sup>, Ilza Maria Oliveira Sousa<sup>2</sup>, Viviane Aparecida Guilherme Damasio<sup>4</sup>, Lais Thiemi Yamane<sup>2</sup>, Eneida de Paula<sup>4</sup>, Rodney Alexandre Ferreira Rodrigues<sup>1,2\*</sup>

**1** Department of Physiological Sciences, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil, **2** Chemical, Biological and Agricultural Research Center (CPQBA), University of Campinas, Paulínia, Brazil, **3** Faculty of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil, **4** Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, Brazil

\* [rodney@cpqba.unicamp.br](mailto:rodney@cpqba.unicamp.br)



**OPEN ACCESS**

**Citation:** Santana de Freitas-Blanco V, Franz-Montan M, Groppo FC, de Carvalho JE, Figueira GM, Serpe L, et al. (2016) Development and Evaluation of a Novel Mucoadhesive Film Containing *Acmella oleracea* Extract for Oral Mucosa Topical Anesthesia. PLoS ONE 11(9): e0162850. doi:10.1371/journal.pone.0162850

**Editor:** Charlene S. Dezzutti, University of Pittsburgh, UNITED STATES

**Received:** April 12, 2016

**Accepted:** August 28, 2016

**Published:** September 14, 2016

**Copyright:** © 2016 Santana de Freitas-Blanco et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was supported by the Brazilian National Council for Scientific and Technological Development (CNPq, #133666/2012-3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

## Abstract

### Purpose

To develop an anesthetic mucoadhesive film containing *Acmella oleracea* (jambu) extract for topical use on oral mucosa.

### Methods

Ethanollic extracts from aerial parts of jambu were prepared by maceration. Pigment removal was obtained by adsorption with activated carbon. Three mucoadhesive films were developed using a film casting method: 10 or 20% of crude jambu extract (10% JB and 20% JB), and 10% of crude jambu extract treated with activated carbon (10% JBC). The mucoadhesive films were characterized regarding their uniformity, thickness, pH, and spilanthal content, and their stability was evaluated during 120 days. Gas chromatography was used to quantify the amount of spilanthal. *In vitro* tests determined the permeation of spilanthal across pig esophageal epithelium mucosa in Franz diffusion cells. Topical anesthetic efficacy was assessed *in vivo* using a tail flick test in mice.

### Results

The three mucoadhesive films showed physical stability and visual appearances suitable for use on oral mucosa. The permeation study revealed that the spilanthal from 10% JBC presented higher flux and permeability coefficient values, compared to 10% or 20% JB ( $p < 0.001$ ). Moreover, 10% JBC showed better topical anesthetic efficacy than the other films ( $p < 0.01$ ).

## Conclusion

Mucoadhesive film containing crude extract of jambu treated with activated carbon is a potential alternative for oral, topical use, encouraging future clinical studies.

## 1. Introduction

A significant fear-triggering agent during dental treatment is the perceived pain during anesthetic injections, which is a source for fear and anxiety that affects up to 30% of the global population [1–3]. In fact, such painful procedures have significantly inhibited patients from seeking appropriate dental treatment [4–7]. Local anesthetics cause a loss of sensitivity by acting on the nerve cell membrane, preventing the generation and conduction of nerve impulses [8]. Topical application of local anesthetics on oral mucosa generally produces superficial anesthesia, useful to reduce the pain during needle insertion or other minimally invasive dental procedures. To achieve an effective topical anesthesia, it is necessary that the topical anesthetic remains in the place of application for a minimum of two minutes [2].

Despite not being designed for oral use, the eutectic mixture of 2.5% lidocaine and 2.5% prilocaine (EMLA Cream<sup>®</sup>) is currently considered the most effective and potent topical anesthetic on oral mucosa [9–14]. Many studies have shown the superior topical anesthesia effectiveness of EMLA in dental procedures in comparison with commercial topical anesthetics, such as 5% lidocaine or 20% benzocaine. The high costs of commercial-synthetic topical anesthetics, which are economically viable only in small portions of the body, along with reports of severe neurotoxicity and cardiotoxicity induced by lidocaine and other topical anesthetics [15–17], justify the development of new substitutes. It is, therefore, relevant and timely to identify and develop new anesthetics suitable for minimizing oral pain associated with dental procedures [3, 18–20].

The constant interest in natural pharmaceuticals has led to great investigation in plant products. *Acmella oleracea* (L.) R.K. Jansen, also referred to as *Spilanthes acmella* L. Murray, is a native South American herb, being very common throughout Southeast Asia [21, 22]. Popularly known as jambu or paracress, it is traditionally used by the northern Brazilian population as a food spice and for the treatment of toothaches and other ailments affecting gums and throat.

Several compounds have been identified in jambu, such as  $\beta$ -caryophyllene, limonene, and thymol in the essential oil, along with vanillic acid, trans-ferulic acid, stigmaterol,  $\beta$ -sitosterol, rhamnolacturonan, scopoletin and alkyl amides in extracts [23–27]. Spilanthol (synonym: affinin), an N-alkyl amide, is one of the bioactive compounds of jambu, being used as flavoring agent in soups, processed vegetables, condiments, chewing gum and dentifrices [28]. When ingested, it causes tingling, numbness and increased salivation [29, 30]. The high concentration of spilanthol found in this species is responsible for both analgesic and anti-inflammatory effects [31, 32]. Studies have evaluated the antinociceptive activity of jambu, and the proposed mechanism of action include the modulation or blocking of transient receptor potential channels subfamily V member 1 (TRPV1) and subfamily A member 1 (TRPA1) [33] and the increased release of gamma-aminobutyric acid [34].

The anesthetic activity of jambu was previously described [35, 36]. Jambu is also classified as safe (GRAS #3783) by the Flavor and Extract Manufacturers Association (FEMA) [37] and the European Food Safety Authority (EFSA) [38]. It presents low toxicity [33, 39, 40] and a widespread popular use. Considering the current lack of effective formulations for topical anesthesia on oral mucosa, jambu is a good candidate for topical anesthesia.

During the development of formulations described here, chitosan was used as a film-forming agent due to its biocompatibility, biodegradability, and non-toxicity. Furthermore, chitosan exhibits buccal mucoadhesive capacity, interacting with negatively-charged groups of the epithelium surface. These characteristics contributed to the selection of chitosan as the film-forming polymer in this study [41, 42].

The aim of the present study was to develop a mucoadhesive film for oral anesthetic application that could be used as a pre-anesthetic before injection in dental procedures.

## 2. Material and Methods


### 2.1 Materials

All the reagents and solvents used were analytical or chromatographic grade. The materials used were as follows: chitosan (deacetylation degree > 75%) (Sigma-Aldrich<sup>®</sup>, MO, USA); Transcutol<sup>®</sup> (ethoxydiglycol) (Gattefossé<sup>®</sup>, Lyon, France); methylparaben, glacial acetic acid, ethanol, ethyl acetate, n-hexane, and methanol (Synth<sup>®</sup>, São Paulo, Brazil); activated carbon (specification type in patent number BR102014022486-6); diatomaceous earth (Celite<sup>®</sup> 545) (Nuclear<sup>®</sup>, São Paulo, Brazil); eutectic mixture of 2.5% lidocaine and 2.5% prilocaine (5% EMLA<sup>®</sup> cream—AstraZeneca<sup>®</sup>, São Paulo, Brazil); chromatography grade methanol (J.T. Baker<sup>®</sup>, PA, USA).

### 2.2 Production of the Crude Ethanolic Extract of Jambu

The plant material used in this study was obtained from the experimental field cultivation at the Chemical, Biological, and Agricultural Research Center (CPQBA), University of Campinas (UNICAMP), located in Paulínia (São Paulo State, Brazil; 22° 47' 52" S, 47° 6' 49" W). The identification was confirmed by Dr. John F. Pruski of Missouri Botanical Garden, USA. A voucher specimen is deposited in the Herbarium of UNICAMP, under catalog #181452. The aerial parts of the jambu were dried, milled, and extraction was performed under mechanical agitation with 95% ethanol (1:5 w/v) in a stainless steel tank for 1.5 h. The remaining residue was separated by filtration, and the extraction process was repeated two more times. The final material was filtered, combined, concentrated under vacuum, and then lyophilized until dryness, being used to determine the final dry mass by weighing, to calculate the yield value. The process yield was determined by the relation between the aerial material used and the final dry mass of the extract. The estimated concentration of spilanthol in the extract was 3%. It was stored in the refrigerator at 8°C until treatment with activated carbon.

**2.2.1 Extract treatment with activated carbon.** The extraction procedure was repeated to confirm the reproducibility of the process, but without the drying step. The extracts obtained were then combined and filtered, being added 4% (w/w) of activated carbon (Fig 1). The mixture was stirred and treated using a particulate activated carbon [43]. The extract was



**Fig 1. Illustration of the crude extract treatment process with activated carbon.**

doi:10.1371/journal.pone.0162850.g001

concentrated under vacuum, lyophilized to dryness, and stored in the refrigerator at 8°C until further use.


### 2.3 Spilanthol Analysis

Analysis of spilanthol in the extract and mucoadhesive films was performed using a gas chromatograph coupled to a mass spectrometer (GC-MS, Agilent® 5890 Series II with Agilent® 5970 EI 70eV mass selective detector). The GC was equipped with a fused silica WCOT column (Agilent® HP5-MS, 30 m x 0.25 mm x 0.25 µm). The analysis conditions were: injector temperature of 220°C, detector temperature of 250°C, temperature program 60–240°C at 3°C/min, sample injection using split mode with 1:40 ratio, helium as carrier gas (0.7 bar, 1 mL/min).

A calibration curve was prepared for the analytical determination of spilanthol, using spilanthol isolated with a centrifugal partition chromatograph (Model 250-SCPC/Spot Prep II®, Armen, Saint-Ave, France) equipped with a quaternary pump, UV/Vis detector, and a fraction collector. The purity of 95.1% was found using GC-FID with area normalization. A stock solution of known concentration was prepared, followed by dilutions performed in volumetric flasks. The limit of detection (0.26 µg.mL<sup>-1</sup> / LOD) and limit of quantification (0.86 µg.mL<sup>-1</sup> / LOQ) was calculated based on the standard deviation of the response and the slope using three independent analytical curves. LOD and LOQ were calculated as 3 and 10 times, respectively, the standard deviation of the response/slope of the calibration curve [44].

### 2.4 Preparation of Mucoadhesive Films Containing *Acmella Oleracea*

The mucoadhesive films were prepared using the casting technique resulting in a gel (Fig 2). Briefly, chitosan (1 g) was dissolved in 1% (v/v) acetic acid solution, with the aid of a



**Fig 2. Illustration of the mucoadhesive film production.**

doi:10.1371/journal.pone.0162850.g002

mechanical homogenizer, and the solution was poured into molds (polystyrene Petri dishes). The final step in the mucoadhesive films production was carried out in a gravity convection drying oven at 40°C for 30 h. Jambu extracts at concentrations of 10% or 20%, with 0.1% of methylparaben and 5% of transcitol were mixed with chitosan gel prepared previously according to patent number BR102014022486-6 [43].

The mucoadhesive films used for the *in vitro* and *in vivo* assays were prepared with 10% crude extract of jambu (10% JB), 20% crude extract of jambu (20% JB), or 10% crude extract of jambu treated with 4% of activated carbon (10% JBC).

## 2.5 Mucoadhesive Films Characterization

Physicochemical evaluation of the mucoadhesive films considered the uniformity of weight and thickness, pH, spilanthal content, and stability.

The mucoadhesive films were cut with a circular punch (15 mm diameter), the mass was measured using an analytical balance (Mettler-Toledo<sup>®</sup>, São Paulo, Brazil), and the thickness was measured using a digital pachymeter (Model Cal II, Tesa<sup>®</sup>, Renens, Switzerland).

The physicochemical stability of the mucoadhesive films was evaluated by packing the materials in waterproof aluminum-lined plastic containers with hermetic closures, and storing them at 40 ± 1°C for 120 days in a climate chamber with no humidity control. Samples were analyzed at 0 and 120 days, considering their appearance, pH, and spilanthal content. The tests were performed in triplicate.

The pH was measured in accordance with the Brazilian Pharmacopeia method [45]. Briefly, deionized water was added to the mucoadhesive films at 1% (w/w), the mixture was ultrasonicated for 2 min, and the pH was measured at room temperature with a pH-meter previously calibrated at pH 7 and 4.

For the determination of spilanthal content, a known mass of mucoadhesive films was added to 1% (m/m) methanol and ultrasonicated for 10 min, followed by filtration through a 0.45 µm membrane filter. The spilanthal quantification was performed according to the analytical conditions described in Section 2.3.

## 2.6 *In vitro* Permeation Studies

*In vitro* permeation studies were carried out using Franz-type vertical diffusion cells with permeation area of 0.6 cm<sup>2</sup> and receptor compartment volume of 4.2 mL. The assays were performed using pig esophagus epithelium obtained from a local slaughterhouse (Frigar Abatedouro Industria e Comercio de Conservas Ltda–ME, located in Sousas-Pedreira Road, Sao Paulo St Brazil, 22° 51' 50.2" S, 46° 59' 59.3" W), according to the method described by Diaz del Consuelo (2005) [46]. The use of pig esophageal epithelium was demonstrated to be an equivalent barrier model to buccal epithelium, since it has similar histological characteristics, permeability, and epithelium composition [46–48]. Moreover, esophageal mucosa has some advantages including larger surface area, absence of damage caused by mastication and easy preparation [46].

Briefly, within 2 h of slaughter, the pig esophageal mucosa was carefully separated from the surrounding tissue with a scalpel. Mucosae with any visual damage at the surface were discarded. The epithelium was separated from the connective tissue after immersion in deionized water at 60°C for 2 min and it was used immediately. This temperature was demonstrated to be unable to alter integrity or permeability of the tissue [46, 49, 50]. The epithelium was placed over a 0.45 µm cellulose filter, with the connective side of the tissue facing the membrane filter, due to its fragility [46, 47]. The membrane filter avoids epithelium damage, without altering

drug permeation. In addition, it reduces the release of impurities from the epithelium to the receptor solution.

The mucoadhesive film, epithelium, and membrane filter were clamped between the donor and receptor compartments. Saline-methanol (70:30, v/v) solution was used in the receptor compartment in order to maintain the sink conditions. The experiment was performed at 37°C during 5 h, under magnetic stirring (400 rpm). Samples (300 µL) were periodically withdrawn from the receptor compartment and immediately replaced by the same volume of solution, taking account of dilution effects. The samples were transferred to chromatography vials and stored in a refrigerator until GC-MS analysis for quantification of spilanthol.

The cumulative amount of spilanthol transported across esophagus epithelium per area unit was plotted along time. The active steady-state flux ( $J$ ) across the barrier was calculated from the slope of the linear portion of the curve. The *lag time* was obtained from the intercept on the time axis, and the permeability coefficient was calculated according to the following equation [46, 50, 51]:

$$J = P \times C_d$$

where  $J$  ( $\mu\text{g}\cdot\text{cm}^{-2}\cdot\text{h}^{-1}$ ) is the spilanthol flux across the epithelium,  $P$  ( $\text{cm}\cdot\text{h}^{-1}$ ) is the permeability coefficient, and  $C_d$  is the spilanthol concentration in the donor compartment ( $\mu\text{g}/\text{cm}^3$ ). All experiments were conducted six times.

## 2.7 In vivo Anesthetic Efficacy

**2.7.1 Animals.** Male Swiss mice (25–40 g) from the Multidisciplinary Center of Biological Investigation of Laboratory Animals (CEMIB–UNICAMP) were maintained at  $25 \pm 2^\circ\text{C}$  under light/dark cycles of 12 h and were kept in their cages with water and food *ad libitum* for at least 7 days before the experiments. The trials were conducted after approval by the Animal Ethics Committee of UNICAMP (protocol #2851–1) and in accordance with the Principles of Laboratory Animal Care (NIH publication #85–23, 1985). The mice were divided into groups of 5 to 6 animals, and each animal was used only once in the experiment.

**2.7.2 Tail-flick test.** The topical anesthetic efficacy of the mucoadhesive films containing jambu extract was evaluated using the tail-flick test, as previously described by de Araujo et al. (2010) [51], which slightly modified Grant et al. (1993) method [52]. Briefly, the animal was placed in an acrylic restraint while maintaining freely the distal portion of the tail (10 cm). The time required for tail removal (latency) was considered as the aversive response to the heat generated by an incandescent lamp (55°C). The baseline was recorded for each animal before the start of the experiment, and only those with baselines below 4 s were considered suitable. The maximum time for contact of the tail with the heat source was set at 10 s (cut-off value) to avoid thermal injury. The three mucoadhesive films prepared were compared to EMLA, used as a positive control (150 mg/animal, corresponding to 7.5 mg of anesthetic) and a negative control (chitosan-bioadhesive without the jambu extract). EMLA was chosen due to its efficacy to reduce pain during needle insertion [53–56] and during local anesthetic injection [57–59].

The mucoadhesive films and EMLA cream were applied 2 cm from the tail base, with the aid of an adhesive tape, for 2 min. The tested substances were then removed, and the nociceptive stimulus was applied to the same region. Measurements were performed immediately after mucoadhesive removal and then every 15 min until the animal returned to its baseline pain response. After use of the animals in the tail-flick test, they were euthanized by cervical dislocation. The duration of analgesia was defined as the increase in the time required for withdrawal of the tail, which was at least 50% higher than the baseline value observed. The data were

expressed as the percentage of the maximum possible effect (MPE, in minutes), using the following relation:

$\%MPE = [(test\ latency - baseline\ latency) / cut-off\ time - baseline\ latency] \times 100$ , being the area under the curve (AUC) recorded for each experimental group [60].

### 3. Statistical Analysis

The *in vitro* permeation data were expressed as a percentage or mean ± SD and subjected to one-way analysis of variance (one-way ANOVA) with the Holm-Sidak *post hoc* test. Analgesia duration was analyzed by Kruskal-Wallis/SNK tests. Correlation between the *in vivo* efficacy and the *in vitro* data was performed using the Pearson's correlation test. All analyses were performed using GraphPad Prism 6.0<sup>®</sup> (GraphPad Software, Inc., USA), considering a significance level of 5%.

## 4. Results

### 4.1 Preparation of Extracts

The ethanolic crude extract of jambu yielded 7.7 ± 0.08%, while the crude extract treated with 4% activated carbon yielded 4.0 ± 0.03%, both on a dry basis. The yield decrease observed for crude extract with 4% activated carbon did not affect the amount of spilanthol. In fact, the spilanthol concentration was increased by using this procedure, being the greenish pigments removed.

### 4.2 Characterization of the Mucoadhesive Films

Table 1 shows the mean (±SD) values for thickness, mass, pH and spilanthol content obtained during the mucoadhesive films stability study.

After 120 days of storage at 40°C, no significant degradation of spilanthol was verified in the mucoadhesive films. The pH remained stable, with minimal changes.

### 4.3 *In vitro* Permeation Studies

Fig 3 shows the spilanthol permeation profiles of the different mucoadhesive films across pig esophagus mucosa. The linear regression analysis showed higher ( $p < 0.0001$ ) spilanthol permeation for 10% JBC mucoadhesive film in comparison with both 10% JB and 20% JB films, which did not differ from each other ( $p = 0.474$ ). Despite the 20% JB film was two-fold more concentrated than 10% JB, the spilanthol permeation profiles of both were similar.

The permeation parameters (flux, lag time, and permeability coefficient) obtained for the experiment illustrated in Fig 3 are provided in Table 2.


The 10% JBC mucoadhesive film presented higher flux of spilanthol across pig esophageal mucosa when compared to both 10% JB ( $p = 0.0003$ ) and 20% JB ( $p = 0.0004$ ), which did not

**Table 1. Physicochemical parameters (Mean±SD) of the mucoadhesive films and spilanthol extracted from mucoadhesive films.**

Extracts	Thickness(in mm)(n = 7)	Mass (in g)(n = 7)	pH (n = 3)		Spilantholcontent (mg/g)	
			Day 0	Day 120	Day 0	Day 120
10% crudeextract	0.45 ± 0.02	0.13 ± 0.01	5.3 ± 0.03	5.4 ± 0.24	17.6 ± 1.41	16.7 ± 0.21
20% crudeextract	0.53 ± 0.01	0.14 ± 0.01	5.1 ± 0.02	5.1 ± 0.05	35.9 ± 5.59	36.2 ± 2.62
10% extract +4% activated carbon	0.52 ± 0.01	0.14 ± 0.01	4.9 ± 0.02	5.3 ± 0.05	22.9 ± 3.39	25.0 ± 0.85

Day 0 = the day of production; Day 120 = the maximum period in the climate chamber.

doi:10.1371/journal.pone.0162850.t001



**Fig 3. Permeation profiles across pig esophagus mucosa of spilanthal from mucoadhesive films applied under finite dose conditions (mean ± SD, n = 6).** 10% JB: mucoadhesive containing 10% of dry crude extract; 20% JB: mucoadhesive containing 20% of dry crude extract; 10% JBC: mucoadhesive containing 10% of dry extract treated with activated carbon (4%).

doi:10.1371/journal.pone.0162850.g003

differ from each other ( $p = 0.8351$ ). However, 10% JBC mucoadhesive film showed a significantly longer lag time ( $p < 0.0001$ ) than the other films. It also presented the highest permeability coefficient ( $p < 0.01$ ), while 10% JB film showed higher permeability coefficient than 20% JB ( $p = 0.0032$ ).

#### 4.4 Tail-Flick Test

Fig 4 shows the tail-flick test results, presented as the percentage of maximum possible effect (%MPE).


**Table 2. Parameters for the permeation (5 h) through pig esophageal mucosa, under finite dose conditions, of spilanthal applied using the three mucoadhesive films tested (mean ± SEM; n = 6; JB: dry crude extract; JBC: dry crude extract treated with 4% of activated carbon).**

Mucoadhesive films(Spilanthal concentration)	Flux( $\mu\text{g}\cdot\text{cm}^2\cdot\text{h}^{-1}$ )	Lag time(h)	Permeability coefficient( $\times 10^{-3}\text{cm}\cdot\text{h}^{-1}$ )
10% JB (2.37 mg)	$9.18 \pm 1.19^a$	$0.16 \pm 0.04^a$	$3.86 \pm 0.50^a$
20% JB (5.13 mg)	$9.52 \pm 1.97^a$	$0.25 \pm 0.06^a$	$1.84 \pm 0.38^b$
10% JBC (3.14 mg)	$17.70 \pm 4.36^b$	$0.58 \pm 0.15^b$	$5.17 \pm 1.39^c$

Each permeation parameter was analyzed separately by ANOVA/Holm-Sidak. Different letters mean significant statistical differences ( $p < 0.05$ ) among the mucoadhesive films.

doi:10.1371/journal.pone.0162850.t002





**Fig 4. Percentage of maximum possible effect (%MPE) values for the different formulations.** Data are presented as mean ± SEM (n = 6). %MPE = [(test latency–baseline latency / cut-off time–baseline latency) × 100].

doi:10.1371/journal.pone.0162850.g004

The 10% JBC mucoadhesive film presented significantly higher ( $p < 0.001$ ) area under the curve ( $AUC_{0-105min}$ ) than the other formulations (Table 3).

As expected, no antinociceptive effect was observed in animals treated with chitosan mucoadhesive films without dry crude extract of jambu (negative controls).

#### 4.5 *In vitro/In vivo* Correlation


Fig 5 shows the Pearson coefficient ( $r$ ) values for the correlation analysis between the permeation parameters (flux and permeability coefficient) and duration of analgesia in the tail-flick test. A strong correlation ( $r = 0.89$ ) was found between analgesia duration and flux, but there was no correlation with the permeability coefficient ( $r = 0.7$ ).

**Table 3. Duration of analgesia and AUC values for the three tested mucoadhesives and EMLA<sup>®</sup>.**

Mucoadhesive films	Analgesia duration in min Median (1 <sup>st</sup> – 3 <sup>rd</sup> quartiles)	AUC <sub>(0–105 min)</sub> mean ± SD
10% JB (n = 6)	6.0 (2–10) <sup>a</sup>	230.4 ± 46.4 <sup>a</sup>
20% JB (n = 6)	30 (30–30) <sup>ab</sup>	417.3 ± 59.6 <sup>b</sup>
10% JBC (n = 6)	60 (33.8–86.2) <sup>b</sup>	754.3 ± 131.2 <sup>c</sup>
EMLA <sup>®</sup> (n = 6)	75 (75–75) <sup>b</sup>	569.8 ± 160.0 <sup>d</sup>

JB: dry crude extract; JBC: dry crude extract treated with 4% of activated carbon; Analgesia duration was analyzed by Kruskal-Wallis/SNK tests; AUC was analyzed by ANOVA/Holm-Sidak tests. Each parameter was analyzed separately. Different letters mean statistically significant differences among the films.

doi:10.1371/journal.pone.0162850.t003



**Fig 5. Pearson coefficient values (mean  $\pm$  SD) for correlation between the studied factors and analgesia duration.** Black circle: 10% JBC; white square: 20% JB; gray triangle: 10% JB.

doi:10.1371/journal.pone.0162850.g005

## 5. Discussion

Spilanthol presents good stability in ethanolic extracts [61]. In addition, ethanol is relatively safe, and it presents low toxicity and cost, being widely used in the extraction of natural products [62, 63]. Therefore, ethanol was the solvent chosen to produce jambu extracts in the present study. The crude jambu extraction yield obtained in this study is comparable to values reported in other studies [64, 65].

Activated carbon has been used to remove chlorophyll or other compounds that might interfere with colorimetric assays, and to isolate bioactive compounds [66, 67]. Activated carbon includes a range of substances with a high degree of porosity and surface area around 800–1500 m<sup>2</sup>/g [68]. It has been also used in many applications, such as removal of color, taste, odor, and other impurities in water [69], and in food processing [70], due to its excellent absorbance capacity, biocompatibility, and lack of toxicity. In the present study, the use of activated carbon was effective to remove some crude extract pigments, such as chlorophyll. The 4% concentration used was found to be the optimal percentage in a preliminary study. Despite the reduction in the mass of extract, a relative increase in the spilanthol concentration was observed.

The mucoadhesive films showed homogeneity of thickness and mass. The average thickness (0.5 mm) of the mucoadhesive films produced in this study was similar to that observed by Aksungur et al. (2004) [71], who developed chitosan bioadhesives with nystatin to treat oral mucositis. Storage at 40°C for 120 days did not affect the physical integrity, pH, or spilanthol content of the adhesives, indicating the good stability of the formulations.

A vertical Franz diffusion cell is commonly used to evaluate the permeation of compounds through the skin or mucosa [72]. The selection of porcine esophageal mucosa as the barrier in this study was based on the similar histological characteristics of this tissue and oral mucosa, such as the presence of non-keratinized stratified squamous epithelium, large surface area and typically intact tissue, favoring the tissue handling during the Franz cells assembly [73].

The *in vitro* permeation of spilanthol in porcine oral mucosa has been investigated elsewhere using Franz-type vertical diffusion cells. Boonen et al. (2010) [74] evaluated two formulations of oral gel (Indolphar<sup>®</sup> and Buccaldol<sup>®</sup>), as well as the pure ethanolic extract of jambu with propylene glycol, using a porcine buccal mucosa (426 ± 10 μm) as permeation barrier.

The differences verified in the concentration of the active compound and the composition of the formulation could lead to different permeation profiles. de Araujo et al. (2010) [51] evaluated multiple formulations of benzocaine, observed almost overlapping permeation profiles in an infinite-dose design and a dramatically different behavior in a finite-dose condition. Boonen et al. (2010) [74] and in the present study, similar permeation profiles of spilanthol were obtained for the films, despite the substantial differences in spilanthol concentration and film composition.

All the formulations evaluated in the current work permeated the pig esophageal epithelium mucosa at higher flux rates than those described by Boonen et al. (2010) [74]. This difference could be explained by the thinner barrier used (mucosa epithelium rather than the thicker dermatomized mucosa). In addition, higher spilanthol concentration (at least 10 times greater) was used in our study, causing an increased flux of the active agent, in agreement with Fick's first law of diffusion.

Nevertheless, the flux is also influenced by the composition of the formulation [75]. Formulations with different concentrations of the same drug may exhibit the same flux, as observed here for the 20% JB mucoadhesive film, which showed a flux very similar with the 10% JB film, despite containing twice the spilanthol concentration. However, the 10% JBC mucoadhesive film presented a flux almost two-fold higher than both 10% JB and 20% JB films, despite the intermediate amount of spilanthol.

These features can also be observed for the lag time and permeability coefficient, with formulations containing the same concentration of the active agent, but different composition on excipients, showing different solubility of the active compound during transport across the barrier [51]. In the present case, the lag time and permeability coefficient were higher for the 10% JBC mucoadhesive film, compared to the other films. Similar findings were reported by Fang et al. (2008) [76] who showed the addition of menthol and ethanol to tetracaine gels doubling the flux and the lag time. The authors suggested that penetration enhancers acted to increase the lag time due to slower distribution in the skin. Another possibility is the presence of a higher concentration of terpenes in the 10% JBC mucoadhesive film, which are typically observed in *Acmella oleracea* extracts [30], and cause an increase in the lag time and in the flux of various drugs [77–79].

A longer lag time, however, should not be confused with a delay in the onset of the anesthetic effect *in vivo*, as demonstrated by Fang et al. (2008) [76]. They observed that a topical tetracaine formulation with the greatest lag time *in vitro* showed the shortest anesthetic onset time in volunteers. The same profile was described by Woolfson et al. (1998) [80], also using tetracaine gel, where the lag time *in vitro* did not affect the *in vivo* onset of anesthesia. Similarly, in the present study, the lag time did not have any effect on the beginning of analgesia *in vivo*.

Consequently, we hypothesize that the removal of pigments by the activated carbon treatment was responsible for the better *in vitro* permeation results achieved with the 10% JBC mucoadhesive. However, this hypothesis should be confirmed in further phytochemical studies. To the best of our knowledge, there are no studies regarding the effect of activated carbon on the phytochemical composition of extracts from plants.

The tail-flick test has been demonstrated to be effective in the antinociceptive activity evaluation of different topical formulations and mucoadhesive films [51, 81–83], and this assay was chosen to evaluate the effectiveness of the mucoadhesive films in the present study.

The antinociceptive effect of jambu has been assessed previously using the tail-flick test. Chakraborty et al. (2004) [39] demonstrated the analgesic activity of its aqueous extract after intraperitoneal administration in albino rats at doses of 100, 200, and 400 mg/kg. Barman et al. (2009) [84] reported the analgesic effect of an ethanolic extract of jambu after subcutaneous administration to albino rats at a dose of 100 mg/kg. Interestingly, the antinociceptive effect was observed with only two minutes of application of the mucoadhesive film on the tail of the animals, showing a rapid onset of action, as desired for dental procedures. The spilanthol concentrations in the mucoadhesive films (10% JB: 2.37 mg; 20% JB: 5.13 mg; 10% JBC: 3.14 mg) were lower than the concentration of anesthetic in the positive control (EMLA<sup>®</sup>: 7.5 mg lidocaine/prilocaine).

The correlation between *in vivo* effectiveness and *in vitro* drug permeation has been investigated in several studies [51, 75, 85–88]. Since *in vivo* studies are usually more expensive, involve ethical aspects, and are more time consuming than *in vitro* studies, efforts to standardize the conditions of *in vitro* experiments and to achieve better replication during the evaluation of different formulations have been performed [89]. The observation of a strong correlation between the permeability coefficient and the duration of analgesia was in agreement with other previous study [51], which observed the analgesia duration increasing with the amount of benzocaine permeated across pig ear skin *in vitro*.

A strong correlation was also found between the flux and the duration of analgesia, which could be explained by greater amounts of spilanthol reaching the receptors responsible for the analgesic effect. In a previous study, Franz-Montan et al. (2013) [75] reported a strong correlation between the flux of benzocaine across pig esophageal epithelium and anesthetic efficacy in volunteers, although the duration of anesthesia was not reported.

The molecular properties of spilanthol could also contribute to the results observed in the present study since it meets all the requirements proposed by Lipinski et al. in 1997 [90], which are known as "rule of five". The five requirements are set of parameters established to predict whether a compound will or will not be orally bioavailable, being widely used to find new molecules for drug development. These five requirements or rules are: 1) octanol-water partition coefficient ( $\log P$ ) less than five; 2) molecular polar surface area (PSA) of 60 to 70 Å; 3) molecular weight should not exceed 500 g/mol; 4) less than 10 groups accepting hydrogen atoms to form hydrogen bonds and 5) less than 5 groups in the molecule donating hydrogen atoms to the hydrogen bonds. Spilanthol has  $\log P$  of 3.4, PSA of 29.1, a molecular weight of 221 g/mol, two atoms of hydrogen acceptors, and one hydrogen donor atom. Thus, it is likely to be permeable through membranes and it could be easily absorbed.

## 6. Conclusions

An orally mucoadhesive film based on chitosan appears to be a promising option for use as a vehicle for the topical application of an anesthetic based on jambu ethanolic extract. The ethnopharmacological uses of this plant species, its use in the culinary area, its safety, and its low toxicity indicate that it can provide an alternative to the topical anesthetic formulations currently available in dentistry.

The optimum formulation developed showed a high degree of *in vitro* permeation and an *in vivo* anesthetic effect similar to EMLA, used as a gold standard topical anesthetic, indicating its potential as an alternative to the topical anesthetics currently found on the market.

## Supporting Information

**S1 Fig. Spilanthol permeated ( $\mu\text{g}/\text{cm}^2$ ).**

(DOCX)

**S2 Fig. Percentage of maximum possible effect (%MPE) values for the different formulations.**

(DOCX)

**S1 Table. Physicochemical parameters of the mucoadhesive films and spilanthol extracted from mucoadhesive films.**

(DOCX)

**S2 Table. Parameters for the permeation (5 h) through pig esophageal mucosa, under finite dose conditions, of spilanthol applied using the three mucoadhesive films tested.**

(DOCX)

**S3 Table. Duration of analgesia and AUC values for the three tested mucoadhesives and EMLA<sup>®</sup>.**

(DOCX)

## Acknowledgments

The authors are grateful to Dr. Volker Bittrich, Maria C. E. Amaral (Department of Plant Biology, Institute of Biology, University of Campinas, Campinas, Brazil), and Dr. John Pruski (Missouri Botanical Garden, USA) for the identification of the plant species. We would also like to thank the Agricultural Division at CPQBA/UNICAMP for providing the plant material used in this work, and Celine Le Quemener (Armen, France) for her invaluable help in the isolation of spilanthol by Centrifugal Partition Chromatography.

## Author Contributions

**Conceptualization:** VSFB MFM RAFR.

**Data curation:** VSFB MFM RAFR FCG.

**Formal analysis:** VSFB MFM FCG.

**Funding acquisition:** RAFR VSFB.

**Investigation:** VSFB LS IMOS VAGD LTY.

**Methodology:** VSFB MFM RAFR.

**Project administration:** RAFR.

**Resources:** FCG JEC GMF EP RAFR.

**Supervision:** RAFR.

**Visualization:** VSFB MFM FCG.

**Writing – original draft:** VSFB.

**Writing – review & editing:** VSFB MFM RAFR FCG.

## References

1. Hmud R, Walsh LJ. Dental anxiety: causes, complications and management approaches. *JMID*. 2009; 2:67–78.
2. Ogle O, Mahjoubi G. Local anesthesia: agents, techniques and complications. *Dent Clin N Am*. 2012; 56:133–48. doi: [10.1016/j.cden.2011.08.003](https://doi.org/10.1016/j.cden.2011.08.003) PMID: [22117947](https://pubmed.ncbi.nlm.nih.gov/22117947/)
3. Gordon D, Heimberg RG, Tellez M, Ismail AI. A critical review of approaches to the treatment of dental anxiety in adults. *Journal of Anxiety Disorders*. 2013; 27(4):365–78. doi: [10.1016/j.janxdis.2013.04.002](https://doi.org/10.1016/j.janxdis.2013.04.002) PMID: [WOS:000321883000002](https://pubmed.ncbi.nlm.nih.gov/WOS:000321883000002/).
4. Schuller AA, Willumsen T, Holst D. Are there differences in oral health and oral health behavior between individuals with high and low dental fear? *Community Dentistry and Oral Epidemiology*. 2003; 31(2):116–21. doi: [10.1034/j.1600-0528.2003.00026.x](https://doi.org/10.1034/j.1600-0528.2003.00026.x) PMID: [WOS:000181633500006](https://pubmed.ncbi.nlm.nih.gov/WOS:000181633500006/).
5. McGrath C, Bedi R. The association between dental anxiety and oral health-related quality of life in Britain. *Community Dentistry and Oral Epidemiology*. 2004; 32(1):67–72. doi: [10.1111/j.1600-0528.2004.00119.x](https://doi.org/10.1111/j.1600-0528.2004.00119.x) PMID: [WOS:000187549400009](https://pubmed.ncbi.nlm.nih.gov/WOS:000187549400009/).
6. Eitner S, Wichmann M, Paulsen A, Holst S. Dental anxiety—an epidemiological study on its clinical correlation and effects on oral health. *Journal of Oral Rehabilitation*. 2006; 33(8):588–93. doi: [10.1111/j.1365-2842.2005.01589.x](https://doi.org/10.1111/j.1365-2842.2005.01589.x) PMID: [WOS:000238757900005](https://pubmed.ncbi.nlm.nih.gov/WOS:000238757900005/).
7. Armfield JM. What goes around comes around: revisiting the hypothesized vicious cycle of dental fear and avoidance. *Community Dentistry and Oral Epidemiology*. 2013; 41(3):279–87. doi: [10.1111/cdoe.12005](https://doi.org/10.1111/cdoe.12005) PMID: [WOS:00031811700010](https://pubmed.ncbi.nlm.nih.gov/WOS:00031811700010/).
8. Malamed S. *Manual de Anestesia Local*. 6 ed. ed. Rio de Janeiro: Elsevier; 2013.
9. Donaldson D, Meechan J. A comparison of the effects of EMLA® cream and topical 5% lidocaine on discomfort during gingival probing. *Anesth Prog*. 1995;(42):7–10.
10. McMillan AS, Walshaw D, Meechan JG. The efficacy of Emla (R) and 5% lignocaine gel for anaesthesia of human gingival mucosa. *British Journal of Oral & Maxillofacial Surgery*. 2000; 38(1):58–61. doi: [10.1054/bjom.1999.0143](https://doi.org/10.1054/bjom.1999.0143) PMID: [WOS:000086091000015](https://pubmed.ncbi.nlm.nih.gov/WOS:000086091000015/).
11. Abu Al-Melh M, Andersson L. Comparison of topical anesthetics (EMLA/Oraqix vs. benzocaine) on pain experienced during palatal needle injection. *Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology*. 2007; 103(5):E16–E20. doi: [10.1016/j.tripleo.2006.11.033](https://doi.org/10.1016/j.tripleo.2006.11.033) PMID: [WOS:000248082300003](https://pubmed.ncbi.nlm.nih.gov/WOS:000248082300003/).
12. Product Monograph for EMLA® Cream and EMLA® Patch [Internet]. 2010
13. Briggs M, Nelson E, Martyn-StJames M. Topical agents or dressings for pain in venous leg ulcers. *Cochrane Database Syst Rev*. 2012.

14. Holst A, Evers H. Experimental Studies Of New Topical Anesthetics On The Oral Mucosa. *Swedish Dental Journal*. 1985; 9(5):185–91. PMID: [WOS:A1985AWM2200001](#).
15. Marra DE, Yip D, Fincher EF, Moy RL. Systemic toxicity from topically applied lidocaine in conjunction with fractional photothermolysis. *Archives of Dermatology*. 2006; 142(8):1024–6. doi: [10.1001/archderm.142.8.1024](#) PMID: [WOS:000239762700010](#).
16. FDA Public Health Advisory: Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures. U. S. Food and Drug Administration Center for Drug Evaluation and Research; 2007.
17. Tran AN, Koo JY. Risk of Systemic Toxicity With Topical Lidocaine/Prilocaine: A Review. *Journal of Drugs in Dermatology*. 2014; 13(9):1118–22. PMID: [WOS:000341803600018](#).
18. Meechan J, Howlett P, Smith B. Factor influencing the discomfort of intraoral needle penetration. *Anesth Prog*. 2005; 52(3):91–4. PMID: [16252738](#)
19. Van Wijk A, Hoogstraten J. Anxiety and pain during dental injections. *J Dent*. 2009; 37(9):700–4. doi: [10.1016/j.jdent.2009.05.023](#) PMID: [19556053](#)
20. Parirokh M, Sadeghi AS, Nakhaee N, Pardakhty A, Abbott PV, Yosefi MH. Effect of Topical Anesthesia on Pain during Infiltration Injection and Success of Anesthesia for Maxillary Central Incisors. *Journal of Endodontics*. 2012; 38(12):1553–6. doi: [10.1016/j.joen.2012.08.011](#) PMID: [WOS:000312479600001](#).
21. Di-Stasi L, Hiruma-Lima C, Santos C, Guimarães E. Asterales medicinais. In: Di-Stasi L, Hiruma-Lima C, editors. *Plantas medicinais na Amazônia e na mata atlântica*. 2 ed. ed. São Paulo: Editora Unesp; 2002. p. 472–3.
22. Lorenzi H, Matos F. *Plantas medicinais no Brasil: nativas e exóticas*. 2 ed. ed. Nova Odessa: Instituto Plantarum de Estudos da Flora Ltda; 2008.
23. Lemos T, Pessoa O, Matos F, Alencar J, Craveiro A. The essential oil of *Spilanthes acmella* Murr. *J Essent Oil Res*. 1991; 3(5):369–70.
24. Baruah R, Leclercq P. Characterization of the essential oil from flower heads of *Spilanthes acmella*. *J Essent Oil Res*. 1993; 5(6):693–5.
25. Ramsewak R, Erickson A, Nair M. Bioactive N-isobutylamides from the flower buds of *Spilanthes acmella*. *Phytochemistry*. 1999; 51:729–32. PMID: [10389272](#)
26. Jirovetz L, Buchbauer G, Wobus A, Shafi M, Abraham G. Essential oil analysis of *Spilanthes acmella* Murr fresh plants from southern India. *J Essential Oil Res*. 2005; 17:429–31.
27. Prachayasittikul S, Suphamong S, Worachartcheewan A, Lawung R, Ruchirawat S, Prachayasittikul V. Bioactive Metabolites from *Spilanthes acmella* Murr. *Molecules*. 2009; 14(2):850–67. doi: [10.3390/molecules14020850](#) PMID: [WOS:000263823400021](#).
28. Miyazawa T, Matsuda T, Muranishi S, Miyake K, inventors; OGAWA KORYO KK (OGAW-Non-standard) OGAWA KORYO KK (OGAW-Non-standard), assignee. Agent for enhancing flavor of food/beverage products such as fish paste, milk beverages and snacks, contains plant extract or plant essential oil containing spilanthal, or spilanthal patent JP2006296356-A; JP4530906-B2. JP2006296356-A 02 Nov 2006 A23L-001/221 200682 Pages: 17 Japanese JP4530906-B2 25 Aug 2010 A23L-001/221 201056 Pages: 16 Japanese.
29. Ley J, Krammer G, Looft J, Reinders G, Bertram H. Structure-activity relationships of trigeminal effects for artificial and naturally occurring alkamides related to spilanthal. *Flavour Science—Recent Advances and Trends*. 2006:21–4.
30. Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. High Therapeutic Potential of *Spilanthes Acmella*: A review. *Excli Journal*. 2013; 12:291–312. PMID: [WOS:000317815500001](#).
31. Cilia-Lopez VG, Juarez-Flores BI, Aguirre-Rivera JR, Reyes-Aguero JA. Analgesic activity of *Heliopsis longipes* and its effect on the nervous system. *Pharmaceutical Biology*. 2010; 48(2):195–200. doi: [10.3109/13880200903078495](#) PMID: [WOS:000273871900014](#).
32. Wu L-c, Fan N-c, Lin M-h, Chu I-r, Huang S-j, Hu C-Y, et al. Anti-inflammatory effect of spilanthal from *Spilanthes acmella* on murine macrophage by down-regulating LPS-Induced inflammatory mediators. *Journal of Agricultural and Food Chemistry*. 2008; 56(7):2341–9. doi: [10.1021/jf073057e](#) PMID: [WOS:000254636400007](#).
33. Nomura ECO, Melissa R, da Silva CF, Hamm LA, Nascimento AM, de Souza LM, et al. Antinociceptive effects of ethanolic extract from the flowers of *Acmella oleracea* (L.) RK Jansen in mice. *Journal of Ethnopharmacology*. 2013; 150(2):583–9. doi: [10.1016/j.jep.2013.09.007](#) PMID: [WOS:000327567900021](#).
34. Rios MY, Aguilar-Guadarrama AB, Gutierrez MD. Analgesic activity of affinin, an alkamide from *Heliopsis longipes* (Compositae). *Journal of Ethnopharmacology*. 2007; 110(2):364–7. doi: [10.1016/j.jep.2006.09.041](#) PMID: [WOS:000245486900019](#).

35. Chakraborty A, Devi BRK, Sanjebam R, Khumbong S, Thokchom IS. Preliminary studies on local anesthetic and antipyretic activities of *Spilanthes acmella* Murr. in experimental animal models. *Indian Journal of Pharmacology*. 2010; 42(5):277–9. doi: [10.4103/0253-7613.70106](https://doi.org/10.4103/0253-7613.70106) PMID: [WOS:000282431500005](https://pubmed.ncbi.nlm.nih.gov/200282431500005/).
36. Fosquiera E, Andrade L, Rotta I, Chaves S, Uchida D, Gazim Z, et al. Effectiveness of *Acmella oleracea* for topical anesthesia on buccal mucosa. *International Association for Dental Research; Foz do Iguaçu, Paraná*2012.
37. States FaEMotU. Safety Assessment of Jambu Oleoresin #3783. Washington, D.C.: FEMA; 2000.
38. Materials EPoFC. Scientific Opinion on Flavouring Group Evaluation 303, Revision 1 (FGE.303Rev1): Spilanthol from chemical group 30. *EFSA Journal*. 2015; 13(1). doi: [10.2903/j.efsa.2015.3995](https://doi.org/10.2903/j.efsa.2015.3995)
39. Chakraborty A, Devi RKB, Rita S, Sharatchandra K, Singh TI. Preliminary studies on anti inflammatory and analgesic activities of *Spilanthes acmella* in experimental animal models. *Indian Journal of Pharmacology*. 2004; 36(3):148–50. PMID: [BCI:BCI200500002249](https://pubmed.ncbi.nlm.nih.gov/BCI:BCI200500002249/).
40. Sharma V, Boonen J, Chauhan NS, Thakur M, De Spiegeleer B, Dixit VK. *Spilanthes acmella* ethanolic flower extract: LC-MS alkylamide profiling and its effects on sexual behavior in male rats. *Phytomedicine*. 2011; 18(13):1161–9. doi: [10.1016/j.phymed.2011.06.001](https://doi.org/10.1016/j.phymed.2011.06.001) PMID: [WOS:000297187200010](https://pubmed.ncbi.nlm.nih.gov/WOS:000297187200010/).
41. Morris G, Kök M, Harding S, Adams G. Polysaccharide drug delivery systems based on pectin and chitosan. *Biotechnol Gen Eng Rev*. 2010;(27):257–84.
42. Morales JO, McConville JT. Manufacture and characterization of mucoadhesive buccal films. *European Journal of Pharmaceutics and Biopharmaceutics*. 2011; 77(2):187–99. doi: [10.1016/j.ejpb.2010.11.023](https://doi.org/10.1016/j.ejpb.2010.11.023) PMID: [WOS:000287619800001](https://pubmed.ncbi.nlm.nih.gov/WOS:000287619800001/).
43. Rodrigues R, Freitas V, Carvalho J, Groppo F, inventorsProcesso de purificação de extrato de jambu, extrato purificado assim obtido, composição anestésica e bioadesivo contendo extrato purificado de jambu; e usos. *Brasil*2014.
44. Guide for Validation of Analytical and Bioanalytical Methods, (2003).
45. Anvisa. Brazilian Pharmacopoeia 5 ed. ed: Ed. Fiocruz; 2010. p. 56.
46. Diaz Del Consuelo I, Pizzolato GP, Falson F, Guy RH, Jacques Y. Evaluation of pig esophageal mucosa as a permeability barrier model for buccal tissue. *J Pharm Sci*. 2005; 94(12):2777–88. doi: [10.1002/jps.20409](https://doi.org/10.1002/jps.20409) PMID: [16258996](https://pubmed.ncbi.nlm.nih.gov/16258996/).
47. Diaz Del Consuelo I, Falson F, Guy RH, Jacques Y. Transport of fentanyl through pig buccal and esophageal epithelia in vitro: influence of concentration and vehicle pH. *Pharm Res*. 2005; 22(9):1525–9. doi: [10.1007/s11095-005-6020-y](https://doi.org/10.1007/s11095-005-6020-y) PMID: [16132365](https://pubmed.ncbi.nlm.nih.gov/16132365/).
48. Diaz-Del Consuelo I, Jacques Y, Pizzolato GP, Guy RH, Falson F. Comparison of the lipid composition of porcine buccal and esophageal permeability barriers. *Arch Oral Biol*. 2005; 50(12):981–7. S0003-9969(05)00133-0 [pii] doi: [10.1016/j.archoralbio.2005.04.008](https://doi.org/10.1016/j.archoralbio.2005.04.008) PMID: [15955526](https://pubmed.ncbi.nlm.nih.gov/15955526/).
49. Kulkarni U, Mahalingam R, Pather I, Li X, Jasti B. Porcine buccal mucosa as in vitro model: effect of biological and experimental variables. *J Pharm Sci*. 2010; 99(3):1265–77. doi: [10.1002/jps.21907](https://doi.org/10.1002/jps.21907) PMID: [19739112](https://pubmed.ncbi.nlm.nih.gov/19739112/).
50. Kulkarni UD, Mahalingam R, Li X, Pather I, Jasti B. Effect of experimental temperature on the permeation of model diffusants across porcine buccal mucosa. *AAPS PharmSciTech*. 2011; 12(2):579–86. doi: [10.1208/s12249-011-9624-z](https://doi.org/10.1208/s12249-011-9624-z) PMID: [21538212](https://pubmed.ncbi.nlm.nih.gov/21538212/); PubMed Central PMCID: [PMCPMC3134678](https://pubmed.ncbi.nlm.nih.gov/PMC3134678/).
51. de Araujo DR, Padula C, Saia Cereda CM, Tofoli GR, Brito RB Jr., de Paula E, et al. Bioadhesive Films Containing Benzocaine: Correlation Between In Vitro Permeation and In Vivo Local Anesthetic Effect. *Pharmaceutical Research*. 2010; 27(8):1677–86. doi: [10.1007/s11095-010-0151-5](https://doi.org/10.1007/s11095-010-0151-5) PMID: [WOS:000279506100017](https://pubmed.ncbi.nlm.nih.gov/WOS:000279506100017/).
52. Grant GJ, Zakowski MI, Vermeulen K, Langeman L, Ramanathan S, Turndorf H. Assessing Local Anesthetic Effect Using The Mouse Tail Flick Test. *Journal of Pharmacological and Toxicological Methods*. 1993; 29(4):223–6. doi: [10.1016/1056-8719\(93\)90029-e](https://doi.org/10.1016/1056-8719(93)90029-e) PMID: [WOS:A1993LU70400007](https://pubmed.ncbi.nlm.nih.gov/WOS:A1993LU70400007/).
53. Svensson P, Petersen JK. Anesthetic effect of EMLA occluded with Orahesive oral bandages on oral mucosa. A placebo-controlled study. *Anesth Prog*. 1992; 39(3):79–82. PMID: [1308377](https://pubmed.ncbi.nlm.nih.gov/1308377/); PubMed Central PMCID: [PMCPMC2148753](https://pubmed.ncbi.nlm.nih.gov/PMCPMC2148753/).
54. Holst A, Evers H. Experimental studies of new topical anaesthetics on the oral mucosa. *Swed Dent J*. 1985; 9(5):185–91. PMID: [3866334](https://pubmed.ncbi.nlm.nih.gov/3866334/).
55. Al-Melh MA, Andersson L. Comparison of topical anesthetics (EMLA/Oraqix vs. benzocaine) on pain experienced during palatal needle injection. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2007; 103(5):e16–20. S1079-2104(06)00937-1 [pii] doi: [10.1016/j.tripleo.2006.11.033](https://doi.org/10.1016/j.tripleo.2006.11.033) PMID: [17331753](https://pubmed.ncbi.nlm.nih.gov/17331753/).
56. Al-Melh MA, Andersson L. Reducing pain from palatal needle stick by topical anesthetics: a comparative study between two lidocaine/prilocaine substances. *J Clin Dent*. 2008; 19(2):43–7. PMID: [18763685](https://pubmed.ncbi.nlm.nih.gov/18763685/).



57. Hutchins HS, Young FA, Lackland DT, Fishburne CP. The effectiveness of topical anesthesia and vibration in alleviating the pain of oral injections. *Anesth Prog.* 1997; 44(3):87–9. PMID: [9481967](#); PubMed Central PMCID: [PMCPMC2148927](#).
58. Meechan JG, Winter RA. A comparison of topical anaesthesia and electronic nerve stimulation for reducing the pain of intra-oral injections. *Br Dent J.* 1996; 181(9):333–5. PMID: [8972953](#).
59. Meechan JG, Howlett PC, Smith BD. Factors influencing the discomfort of intraoral needle penetration. *Anesth Prog.* 2005; 52(3):91–4. doi: [10.2344/0003-3006\(2005\)52\[91:FITDOI\]2.0.CO;2](#) PMID: [16252738](#); PubMed Central PMCID: [PMCPMC1586791](#).
60. Yu HY, Li SD, Sun P. Kinetic and dynamic studies of liposomal bupivacaine and bupivacaine solution after subcutaneous injection in rats. *Journal of Pharmacy and Pharmacology.* 2002; 54(9):1221–7. doi: [10.1211/002235702320402062](#) PMID: [WOS:000178617700007](#).
61. Bae SS, Ehrmann BM, Etefagh KA, Cech NB. A Validated Liquid Chromatography-Electrospray Ionization-Mass Spectrometry Method for Quantification of Spilanthalol in *Spilanthes acmella* (L.) Murr. *Phytochemical Analysis.* 2010; 21(5):438–43. doi: [10.1002/pca.1215](#) PMID: [WOS:000281460000007](#).
62. Rodrigues RAF, Foglio MA, Boaventura S, Santos AD, Rehder VLG. Optimization of the extraction and isolation of the antimalarial drug artemisinin from *Artemisia annua* L. *Quimica Nova.* 2006; 29(2):368–72. doi: [10.1590/s0100-40422006000200030](#) PMID: [WOS:000236414600030](#).
63. Zhao W. Extraction and isolation of natural products. In: Rensheng X, Yang Y, Zhao W, editors. *Introduction to natural products chemistry.* 1 ed ed: CRC Press; 2011. p. 5–25.
64. Yadav R, Yadav N, Kharya M, Savadi R. Preliminary studies on diuretic effect of *Spilanthes acmella* leaves extracts in rats. *Int J Pharm Pharm Sci.* 2011; 3(3):245–7.
65. Dias A, Santos P, Seabra I, Junior R, Braga M, Sousa H. Spilanthalol from *Spilanthes acmella* flowers, leaves and stems obtained by selective supercritical dioxide extraction. *J Supercrit fluids.* 2012; 61:62–70.
66. Scheepers JC, Malan SF, Du Preez JL, Van Dyk S. The high performance liquid chromatography (HPLC) analysis of ultraviolet (UV) irradiated chlorophyll a and secondary plant compounds. *African Journal of Biotechnology.* 2011; 10(74):16976–85. doi: [10.5897/ajb11.1999](#) PMID: [WOS:000298560300033](#).
67. Naik AD, Menegatti S, Reese HR, Gurgel PV, Carbonell RG. Process for purification of monoclonal antibody expressed in transgenic *Lemna* plant extract using dextran-coated charcoal and hexamer peptide affinity resin. *Journal of Chromatography A.* 2012; 1260:61–6. doi: [10.1016/j.chroma.2012.08.043](#) PMID: [WOS:000309782800008](#).
68. Rodriguez-Reinoso F. Activated carbon and adsorption. In: Cahn R, Kramer E, Mahajan S, editors. *Encyclopedia of materials: science and technology:* Elsevier; 2001. p. 22–34.
69. Bansal R, Goyal M. Activated carbon and its surface structure. In: Goyal M, editor. *Activated carbon adsorption.* 1 ed. ed: CRC Press; 2005. p. 1–65.
70. Ozsoy HD, van Leeuwen J. Removal of color from fruit candy waste by activated carbon adsorption. *Journal of Food Engineering.* 2010; 101(1):106–12. doi: [10.1016/j.jfoodeng.2010.06.018](#) PMID: [WOS:000281212300014](#).
71. Aksungur P, Sungur A, Unal S, Iskit AB, Squier CA, Senel S. Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studies. *Journal of Controlled Release.* 2004; 98(2):269–79. doi: [10.1016/j.jconrel.2004.05.002](#) PMID: [WOS:000223112500007](#).
72. OECD. Test guideline 428: Skin absorption: in vitro method. Paris: Organization for Economic Cooperation and Development, 2004.
73. Diaz Del Consuelo I, Pizzolato GP, Falson F, Guy RH, Jacques Y. Evaluation of pig esophageal mucosa as a permeability barrier model for buccal tissue. *Journal of Pharmaceutical Sciences.* 2005; 94(12):2777–88. doi: [10.1002/jps.20409](#) PMID: [WOS:000233733300017](#).
74. Boonen J, Baert B, Burvenich C, Blondeel P, De Saeger S, De Spiegeleer B. LC-MS profiling of N-alkylamides in *Spilanthes acmella* extract and the transmucosal behaviour of its main bio-active spilanthalol. *Journal of Pharmaceutical and Biomedical Analysis.* 2010; 53(3):243–9. doi: [10.1016/j.jpba.2010.02.010](#) PMID: [WOS:000280435800004](#).
75. Franz-Montan M, Saia Cereda CM, Gaspari A, Goncalves da Silva CM, de Araujo DR, Padula C, et al. Liposomal-benzocaine gel formulation: correlation between in vitro assays and in vivo topical anesthesia in volunteers. *Journal of Liposome Research.* 2013; 23(1):54–60. doi: [10.3109/08982104.2012.742536](#) PMID: [WOS:000314308200007](#).
76. Fang C, Liu Y, Ye X, Rong Z-x, Feng X-m, Jiang C-b, et al. Synergistically enhanced transdermal permeation and topical analgesia of tetracaine gel containing menthol and ethanol in experimental and clinical studies. *European Journal of Pharmaceutics and Biopharmaceutics.* 2008; 68(3):735–40. doi: [10.1016/j.ejpb.2007.02.007](#) PMID: [WOS:000255317800028](#).

77. Cornwell PA, Barry BW. SESQUITERPENE COMPONENTS OF VOLATILE OILS AS SKIN PENETRATION ENHANCERS FOR THE HYDROPHILIC PERMEANT 5-FLUOROURACIL. *Journal of Pharmacy and Pharmacology*. 1994; 46(4):261–9. PMID: [WOS:A1994NF90700004](#).
78. Nokhodchi A, Sharabiani K, Rashidi MR, Ghafourian T. The effect of terpene concentrations on the skin penetration of diclofenac sodium. *International Journal of Pharmaceutics*. 2007; 335(1–2):97–105. doi: [10.1016/j.ijpharm.2006.10.041](#) PMID: [WOS:000246092300012](#).
79. Yang Z, Teng Y, Wang H, Hou H. Enhancement of skin permeation of bupivacaine by limonene via reservoir type transdermal patch: Formulation design and biopharmaceutical evaluation. *International Journal of Pharmaceutics*. 2013; 447(1–2):231–40. doi: [10.1016/j.ijpharm.2013.02.048](#) PMID: [WOS:000317310500029](#).
80. Woolfson AD, McCafferty DF, Moss GP. Development and characterisation of a moisture-activated bioadhesive drug delivery system for percutaneous local anaesthesia. *International Journal of Pharmaceutics*. 1998; 169(1):83–94. doi: [10.1016/s0378-5173\(98\)00109-4](#) PMID: [WOS:000075092700009](#).
81. Shin S, Cho C, Yang K. Development of lidocaine gels for enhanced local anesthesia action. *Int J Pharm*. 2004; 287:73–8. PMID: [15541914](#)
82. Kolesnikov Y, Soritsa D. Analgesic synergy between topical opioids and topical non-steroidal anti-inflammatory drugs in the mouse model of thermal pain. *European Journal of Pharmacology*. 2008; 579(1–3):126–33. doi: [10.1016/j.ejphar.2007.10.014](#) PMID: [WOS:000252979200016](#).
83. Arrau S, Delporte C, Cartagena C, Rodriguez-Diaz M, Gonzalez P, Silva X, et al. Antinociceptive activity of Quillaja saponaria Mol. saponin extract, quillaic acid and derivatives in mice. *Journal of Ethnopharmacology*. 2011; 133(1):164–7. doi: [10.1016/j.jep.2010.09.016](#) PMID: [WOS:000286854100023](#).
84. Barman S, Sahu N, Dutta S, S. D. Anti-inflammatory and analgesic activity of leaves of *Spilanthes acmella* (ELSA) in experimental animal models. *Pharmacology online*. 2009; 1:1027–34.
85. Godin B, Touitou E. Transdermal skin delivery: Predictions for humans from in vivo, ex vivo and animal models. *Advanced Drug Delivery Reviews*. 2007; 59(11):1152–61. doi: [10.1016/j.addr.2007.07.004](#) PMID: [WOS:000251355400008](#).
86. Franz TJ, Lehman PA, Raney SG. Use of Excised Human Skin to Assess the Bioequivalence of Topical Products. *Skin Pharmacology and Physiology*. 2009; 22(5):276–86. doi: [10.1159/000235828](#) PMID: [WOS:000270556500006](#).
87. Mohammed D, Matts P, Hardgraft J, ME L. In vitro-in vivo correlation in skin permeation. *Pharm Res*. 2014;394–400. doi: [10.1007/s11095-013-1169-2](#) PMID: [23943545](#)
88. Franz-Montan M, Baroni D, Brunetto G, Vieira Sobral VR, Goncalves da Silva CM, Venancio P, et al. Liposomal lidocaine gel for topical use at the oral mucosa: characterization, in vitro assays and in vivo anesthetic efficacy in humans. *Journal of Liposome Research*. 2015; 25(1):11–9. doi: [10.3109/08982104.2014.911315](#) PMID: [WOS:000348991200002](#).
89. Lehman PA, Raney SG, Franz TJ. Percutaneous Absorption in Man: In vitro-in vivo Correlation. *Skin Pharmacology and Physiology*. 2011; 24(4):224–30. doi: [10.1159/000324884](#) PMID: [WOS:000290778400007](#).
90. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews*. 1997; 23(1–3):3–25. doi: [10.1016/s0169-409x\(96\)00423-1](#) PMID: [WOS:A1997WH25900002](#).